Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GBT440 300 mg Capsules in Healthy Subjects
NCT02567695Phase 1Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of voxelotor in sickle cell disease (SCD) (2 arms), sponsored by Global Blood Therapeutics. Primary endpoints: Maximum observed concentration at Day 28, Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration at Day 28 and 1 more. Started Sep 2015; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02567695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567695.